KLOW Peptide Composition: What Is in the 80 mg Vial

The gist of the vial

Here is the plain-English start. The KLOW peptide composition is easy to picture as a flower with four petals of different sizes. The most widely listed research vial is 80 mg total, split as GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg and KPV 10 mg. That makes GHK-Cu — the copper peptide — about 62.5% of the vial, the giant petal; the other three are equal and smaller.

One more plain fact: this is a co-formulation, which just means four separate peptides dissolved together in one vial. They do not merge into a new single chemical. So the 80 mg is the combined weight of four distinct molecules sharing a vial, not the weight of one compound. The numbers below describe vial content for laboratory handling — never a human dose.

What is in the 80mg KLOW peptide vial?

The most widely listed research-vial composition is 80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg, co-dissolved at fixed mass ratios ^[4][6]. The four stay separate molecules — a co-formulation, not a single new compound. No FDA-approved or pharmacopeial KLOW combination product exists; the figures are vendor-listed for research handling only. Each component carries its own identity: GHK-Cu (Copper Tripeptide-1, MW 402.92 Da, CAS 89030-95-5), KPV (MW 342.44 Da, CAS 67727-97-3), BPC-157 (MW 1419.53 Da, CAS 137525-51-0), and TB-500 (Ac-LKKTET-Q, MW 889.02 Da).

What ratio of peptides is in KLOW?

The canonical research ratio is 50:10:10:10 by mass — GHK-Cu : BPC-157 : TB-500 : KPV — making GHK-Cu about 62.5% of the 80 mg vial. The other three components are equal at 10 mg each (12.5% apiece). No FDA-approved or pharmacopeial KLOW combination exists, so this ratio is vendor-listed for laboratory handling, not a regulated formulation. It is the share that sizes the cyan petal far larger than the rest in the four-petal diagram.

Why is GHK-Cu the largest ingredient in KLOW?

GHK-Cu is the mass-dominant component — about 50 of 80 mg, roughly 62.5%. Two things justify the share. It has the broadest matrix-remodeling and gene-expression literature of the four: collagen synthesis in human fibroblasts ^[6], a transcriptome-wide shift across roughly 31.2% of assayed genes ^[5], and the widest tissue-remodeling profile ^[4][7]. And it has the longest human track record — decades of topical cosmetic and wound-healing data ^[4], with quantified transdermal copper delivery ^[8]. The canonical ratio reflects GHK-Cu's standing as the most-validated of the four peptides.

Why is KLOW peptide blue?

The blue tint comes from copper. The mass-dominant GHK-Cu component (Copper Tripeptide-1) is the tripeptide Gly-His-Lys chelated 1:1 to a copper(II) ion ^[4], and copper(II) complexes are characteristically blue. So the color is a property of the GHK-Cu chemistry — and of its dominant 50 mg share — not of the blend as a whole. The other three petals (BPC-157, TB-500, KPV) carry no copper and contribute no color; the cyan you see is the copper petal showing through.

Why KLOW is a co-formulation, not a single molecule

The KLOW blend is a co-formulation: multiple distinct compounds dissolved together at fixed ratios, remaining separate molecules rather than forming a single new chemical entity. There is no single PubChem CID, UNII or CAS for KLOW, because a mixture is not a defined substance — per-component identifiers exist instead ^[4][6]. This matters for honesty: there is nothing to test as "KLOW" the molecule, and there is no single half-life, no single dose-response, and no single safety profile. The four peptides keep their own chemistry inside one vial, which is exactly why the dosage and the pharmacokinetic mismatch is built in from the start.